Association between CISD2 expression and clinicopathological features and prognosis in gastric cancer: a systematic review, meta-analysis, and database validation
- 1The First School of Clinical Medicine, Gansu University of Chinese Medicine
- 2Department of Radiology, Gansu Provincial Hospital
- 3Department of Oncology I, Gansu Provincial Hospital of Traditional Chinese Medicine
Abstract
Objective: This study conducted an exploratory hypothesis-generating investigation to assess the relationship between CDGSH iron sulfur domain 2 (CISD2) and gastric cancer (GC) via meta-analysis supplemented by independent in silico database analysis.
Methods: We systematically searched 7 major databases including Wan Fang, VIP, CNKI, SinoMed, Web of Science, The Cochrane Library, and PubMed from database inception to July 2026 for studies reporting CISD2 expression data in GC patients. Two researchers independently performed literature screening, data extraction, and quality assessment. Stata 12.0 was used to conduct the meta-analysis of protein-level CISD2 expression data from immunohistochemistry (IHC) studies. The Kaplan-Meier plotter database was used as an independent complementary analysis to explore the association between CISD2 transcript-level expression and GC prognosis. The study protocol was registered in PROSPERO (CRD42023490404).
Results: Three high-quality studies with a total of 1318 participants were finally included. The exploratory meta-analysis showed no statistically significant association between CISD2 protein expression and age, gender, lymphatic invasion, TNM stage, or histological grade in GC patients. A suggestive negative correlation was observed between CISD2 IHC expression and tumor invasion depth, with a pooled OR of 0.57 (95% CI : 0.41 - 0.79, P = 0.001). The independent transcript-level in silico analysis from the Kaplan-Meier plotter provided complementary prognostic evidence, showing that elevated CISD2 mRNA expression was significantly correlated with poor first progression ( HR = 1.3, P = 0.04) and reduced overall survival ( HR = 1.27, P = 0.041) in GC patients.
Conclusion: This exploratory study generates preliminary hypotheses that CISD2 may have a potential association with GC progression and prognosis. Given the limited number of included studies and the distinct data types across analyses, large-scale prospective studies and mechanistic investigations are urgently required to verify these associations before any clinical application of CISD2 as a biomarker can be established.
Related
- Immunohistochemical Expression of M30, BCL-2, BAX, and Ki-67 in Pancreatic Ductal Adenocarcinoma: Association with Clinicopathological Features
- Association of VCP/p97 Expression with Clinicopathological Features and Overall Survival in Endometrioid Endometrial Carcinoma
- Expression of glycolytic enzymes (GLUT1, HK2, PKM2, LDH-A) and their association with tumour stage and clinicopathological characteristics in breast cancer patients
- Expression, association with clinicopathological features and prognostic potential of FOXR2, mTOR, HIF−1α and PKM2 in high−grade serous carcinoma of the ovary
- Clinicopathological characteristics and prognosis of melanoma: A retrospective cohort study in Xinjiang, China
BibTeX
@article{liang2026association,
title = {{Association between CISD2 expression and clinicopathological features and prognosis in gastric cancer: a systematic review, meta-analysis, and database validation}},
author = {Tong Liang and Yaqiong Cui and Hongmei Song},
journal = {Frontiers in Oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1965844},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1965844/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Association between CISD2 expression and clinicopathological features and prognosis in gastric cancer: a systematic review, meta-analysis, and database validation
AU - Tong Liang
AU - Yaqiong Cui
AU - Hongmei Song
PY - 2026
DA - 2026/10/20
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1965844
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1965844/full
AB - Objective: This study conducted an exploratory hypothesis-generating investigation to assess the relationship between CDGSH iron sulfur domain 2 (CISD2) and gastric cancer (GC) via meta-analysis supplemented by independent in silico database analysis. Methods: We systematically searched 7 major databases including Wan Fang, VIP, CNKI, SinoMed, Web of Science, The Cochrane Library, and PubMed from database inception to July 2026 for studies reporting CISD2 expression data in GC patients. Two researchers independently performed literature screening, data extraction, and quality assessment. Stata 12.0 was used to conduct the meta-analysis of protein-level CISD2 expression data from immunohistochemistry (IHC) studies. The Kaplan-Meier plotter database was used as an independent complementary analysis to explore the association between CISD2 transcript-level expression and GC prognosis. The study protocol was registered in PROSPERO (CRD42023490404). Results: Three high-quality studies with a total of 1318 participants were finally included. The exploratory meta-analysis showed no statistically significant association between CISD2 protein expression and age, gender, lymphatic invasion, TNM stage, or histological grade in GC patients. A suggestive negative correlation was observed between CISD2 IHC expression and tumor invasion depth, with a pooled OR of 0.57 (95% CI : 0.41 - 0.79, P = 0.001). The independent transcript-level in silico analysis from the Kaplan-Meier plotter provided complementary prognostic evidence, showing that elevated CISD2 mRNA expression was significantly correlated with poor first progression ( HR = 1.3, P = 0.04) and reduced overall survival ( HR = 1.27, P = 0.041) in GC patients. Conclusion: This exploratory study generates preliminary hypotheses that CISD2 may have a potential association with GC progression and prognosis. Given the limited number of included studies and the distinct data types across analyses, large-scale prospective studies and mechanistic investigations are urgently required to verify these associations before any clinical application of CISD2 as a biomarker can be established.
SN - 2234-943X
ER -